DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for ...(herently uncertain and are simplypoint-i...),Health

Date:8/19/2007

herently uncertain and are simply point-in-time estimates based on a combination of facts and factors currently known by us about which we cannot be certain or even relatively confident. Actual results or events will surely differ and may differ materially from our forward-looking statements as a result of many factors, some of which we may not be able to predict or may not be within our control. Such factors may also materially adversely affect our ability to achieve our objectives and to successfully develop and commercialize our product candidates, including our ability to:

-- raise substantial additional capital in order to fund operations;

-- obtain and maintain all necessary patents, licenses and other

intellectual property rights;

-- demonstrate the safety and efficacy of product candidates at each stage

of development;

-- meet our development schedule for our product candidates, including

with respect to clinical trial initiation, enrollment and completion;

-- meet applicable regulatory standards and receive required regulatory

approvals on our anticipated time schedule or at all;

-- meet or require our partners to meet obligations and achieve milestones

under our license and other agreements;

-- maintain collaborations as required with pharmaceutical partners;

-- seek and evaluate strategic alternatives, including with respect to

collaborations and partnerships for certain of our development programs

and compounds; and

-- produce drug candidates in commercial quantities at reasonable costs

and compete successfully against other products and companies.

You should also refer to the risks discussed in our filings with the Securities and Exchange Commission including those contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 that was filed on March 30, 2007 and our Quarterly Report on Form 10-Q fo
'/>"/>

SOURCE DOV Pharmaceutical, Inc. Copyright©2007 PR Newswire.

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference